EndLink: An Internet-based End of Life Care Education Program <u>http://endlink.lurie.northwestern.edu</u>

MORPHINE DOSING

1. Initial Dosing for Constant Pain

For a patient with significant previous opioid exposure, calculate the starting dose for an immediate-release opioid using the equianalgesic table (to begin the new opioid you will cut back on this dose as appropriate) and dose q 4h, or

For a patient who is relatively opioid naive and in significant pain, start dosing with 10 to 30 mg of immediate-release oral morphine liquid concentrate or tablet q 4h, or

For a patient with stable pain that is not severe, start extended-release oral morphine at a dose of 15 or 30 mg twice daily or 30 to 60 mg once daily (depending on formulation).

Then, prescribe a "breakthrough" or rescue dose that is 5% to 15% of the total dose in use every 24 hours and offer it q 1h po prn. Ask the patient and family to record in a diary all medication taken.

To convert to an extended-release preparation, calculate the total morphine dose required to achieve comfort during a 24-hour period. Either divide by 2 to get the q 12h dose of extended-release morphine to prescribe routinely, or give the total dose once daily (depending on the product).

Always prescribe a breakthrough dose of immediate release morphine using liquid concentrate or tablet. Offer 5% to 15% of the 24-hour dose q 1h po prn.

Monitor closely and titrate as needed

2. Increasing the Dose

If a patient requires more than 2 to 4 breakthrough doses in a 24-hour period on a routine basis, consider increasing the dose of the extended-release preparation.

Determine the total amount of morphine used (routine + breakthrough) and administer the total in divided doses q 12h or q 24h (depending on the product).

Recalculate the breakthrough so that it is always 5% to 15% of the total daily dose and offer it q 1h po.

NB: In the patient with cancer, the most common reason for an increased dose is worsened pathology, not pharmacological tolerance.

The EndLink program is funded with a grant from the National Cancer Institute grant (R25 CA76449) to Sara J. Knight, Ph.D., at the Robert H. Lurie Comprehensive Cancer. This material used in this document was adapted from the EPEC project (Education for Physicians on End-of-life Care).